Stay updated on Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial
Sign up to get notified when there's something new on the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page.

Latest updates to the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe clinical-trial record for neoadjuvant pembrolizumab in stage IIB/C melanoma is displayed, with its study design, participant criteria, locations, and outcome measures. A study protocol and statistical analysis plan are also listed among the study documents.SummaryDifference52%

- Check9 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0; the study page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check16 days agoChange DetectedA sitewide NIH banner announces updates and FAQs about replacing the term “Artificial Intelligence” with “Super Intelligence” during a transition.SummaryDifference1%

- Check23 days agoChange DetectedThe site revision shown in the footer changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check30 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check44 days agoChange DetectedThe 403 Forbidden page content and its Home navigation text were removed, resulting in the study details page becoming accessible again.SummaryDifference0.5%

Stay in the know with updates to Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page.